Therapy to Obese Type 2 Diabetes Mellitus:How Far Will We Go Down the Wrong Road?

被引:0
|
作者
HENG Xianpei [1 ]
LI Xiujun [2 ]
LI Liang [1 ]
YANG Liuqing [1 ]
WANG Zita [1 ]
HUANG Suping [3 ]
机构
[1] 不详
[2] Department of Endocrinology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine
[3] 不详
[4] West China Medical Center of Sichuan Medical University West China University of Medical Science
[5] Academy of Integrative Medicine Fujian, Fujian University of Traditional Chinese Medicine
[6] 不详
关键词
D O I
暂无
中图分类号
R587.1 [糖尿病];
学科分类号
摘要
Traditional glucose-lowering chemical agents, including various types of insulin and insulin secretagogues, insulin sensitizers, gliptins, etc., are based on diabetic pathogenesis of insulin resistance(IR) and islet insufficiency. Numerous evidence-based medical studies have shown that these traditional hypoglycemic chemical agents do not provide cardiovascular benefit to patients with type 2 diabetes mellitus(T2 DM) and may even increase the risk of all-cause mortality. Based on research evidence published to date, these studies show that overload of energy could increase the incidence and prevalence of T2 DM, and reduction in the heat load can significantly reduce the incidence of T2 DM. Therefore, the essence of T2 DM is heat overload, meaning heat overload is the etiology of obese T2 DM. At the same time, results of numerous studies show that heat overloading is the cause of IR. IR and islet dysfunction are protective factors in intervening with heat overload.These drugs, which are based on the mechanisms of IR and islet insufficiency, increase caloric reserve and cause or worsen obesity, which is equivalent to exacerbating the basic etiology and the cardiovascular risk factor of T2 DM. Thus, a reasonable strategy for prevention and treatment of obese T2 DM appears to promote the negative balance of calories and the elimination of caloric reserves. Chinese herbal medicines can promote negative balance of heat in many aspects, which can bring new hope for prevention and treatment of T2 DM.
引用
收藏
页码:62 / 71
页数:10
相关论文
共 50 条
  • [21] Metformin in type 2 diabetes: What if we get it wrong?
    Boussageon, Remy
    PRESSE MEDICALE, 2013, 42 (02): : 132 - 133
  • [22] THE IMMUNOINFLAMMATORY PROCESS IN TYPE 2 DIABETES MELLITUS. HOW CAN WE HELP?
    Valdes-Ramos, Roxana
    ANNALS OF NUTRITION AND METABOLISM, 2017, 71 : 163 - 163
  • [23] PROGRESSIVE RHEUMATOID-ARTHRITIS - HOW FAR SHOULD WE GO WITH MEDICAL THERAPY
    ANASTASSIADES, TP
    DWOSH, IL
    FORD, PM
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1980, 122 (11) : 1223 - &
  • [24] Sulfonylureas in the therapy of type 2 diabetes mellitus: where do we stand today?
    Del Prato, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (05): : S1 - S1
  • [25] Therapie des Diabetes mellitus Typ 2 Therapy of diabetes mellitus type 2
    S. Wiegand
    Monatsschrift Kinderheilkunde, 2005, 153 : 936 - 944
  • [26] Not every obese child has type 2 Diabetes Mellitus
    Koutaki, Diamanto
    Vourdoumpa, Aikaterini
    Vasilakis, Ioannis-Anargyros
    Sertedaki, Amalia
    Charmandari, Evangelia
    Paltoglou, George
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 257 - 257
  • [27] Variations of SPARC in obese patients with type 2 diabetes mellitus
    刘锴
    China Medical Abstracts(Internal Medicine), 2014, 31 (03) : 149 - 150
  • [28] Pharmacologic therapy for type 2 diabetes mellitus
    DeFronzo, RA
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) : 281 - 303
  • [29] Nateglinide therapy for type 2 diabetes mellitus
    Levien, TL
    Baker, DE
    Campbell, RK
    White, JR
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (11) : 1426 - 1434
  • [30] Incretin therapy for diabetes mellitus type 2
    Holst, Jens Juul
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2020, 27 (01) : 2 - 10